Tecovirimat manufacturers
- Tecovirimat
-
- $0.00 / 1kgkg
-
2026-04-24
- CAS:816458-31-8
- Min. Order: 1kgkg
- Purity: 99%
- Supply Ability: 3000kg
- Tecovirimat
-
- $1.00 / 1g
-
2026-04-17
- CAS:816458-31-8
- Min. Order: 1g
- Purity: 99
- Supply Ability: 1000
- Tecovirimat
-
- $0.00 / 1g
-
2026-03-27
- CAS:816458-31-8
- Min. Order: 1g
- Purity: 98% HPLC
- Supply Ability: 1kg
|
| | Tecovirimat Basic information |
| Product Name: | Tecovirimat | | Synonyms: | tecovirimat;rel-N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl]-4-(trifluoromethyl)benzamide;Tecovirimat USP/EP/BP;Special Kao Wei Rui | | CAS: | 816458-31-8 | | MF: | C19H15F3N2O3 | | MW: | 376.332 | | EINECS: | | | Product Categories: | API | | Mol File: | 816458-31-8.mol |  |
| | Tecovirimat Chemical Properties |
| Melting point | 194-195 ºC | | density | 1.53 | | storage temp. | -20°C Freezer | | solubility | Dichloromethane (Slightly), DMSO Slightly() | | form | Solid | | color | White to Off-White | | InChI | InChI=1/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25)/t10-,11+,12+,13-,14-,15+ | | InChIKey | CSKDFZIMJXRJGH-VWLPUNTINA-N | | SMILES | C(F)(C1C=CC(=CC=1)C(=O)NN1C(=O)[C@@]2([H])[C@@]([H])(C1=O)[C@@]1([H])C=C[C@]2([H])[C@]2([H])C[C@]12[H])(F)F |&1:14,16,20,24,26,29,r| |
| | Tecovirimat Usage And Synthesis |
| Chemical Properties | The water solubility of ST-246 is very poor, the solubility in water is about 3 μg/ml, which is a low solubility drug; the solubility of ST-246 increases with the increase of p H, and the solubility in alkaline environment is higher than that in weakly alkaline and acidic environment. | | Uses | Tecovirimat is an orally bioavailable antipoxvirus compound inhibits extracellular virus formation and protects mice from lethal orthopoxvirus, including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), and variola viruses. | | Pharmacokinetics | At the recommended oral dosage of 600 mg every 12 hours administered in healthy adults weighing less than 120 kg, the mean steady-state values of tecovirimat AUC0-24hr, Cmax, and Ctau/trough are 29816 hr¤ng/mL (n, CV: 43, 34%), 2159 ng/mL (n, CV: 46, 32%), and 845 ng/mL (n, CV: 45, 47%), respectively. At the recommended intravenous dosage of 200 mg every 12 hours administered by IV infusion over 6 hours in healthy adults, the mean steady-state values of tecovirimat AUC0-24hr, Cmax, and Cmin are 39405 hr.ng/mL (n, CV: 22, 23%), 2630 ng/mL (n, CV: 22, 22%), and 747 ng/mL (n, CV: 22, 29%). Refer to Table 7 for pharmacokinetic parameters of tecovirimat. Tecovirimat steady-state is achieved by Day 4-6. | | Side effects |
Common side effects of TPOXX (Tecovirimat) include: headache, nausea, abdominal pain, and vomiting.
TPOXX (Tecovirimat) may cause serious side effects, including: hives, difficulty breathing, and swelling of your face, lips, tongue, or throat.
|
| | Tecovirimat Preparation Products And Raw materials |
|